Immutep (IMMP) Receivables (2011 - 2025)
Immutep's (IMMP) quarterly Receivables came in at $24.1 million in Q4 2025, up 439.65% YoY from $4.5 million in Q4 2024, and up 281.55% on a QoQ basis from $6.3 million in Q2 2025.
Immutep (IMMP) Receivables (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Receivables data on file, last reported at $24.1 million in Q4 2025.
- Quarterly Receivables rose 439.65% year-over-year to $24.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.1 million (up 439.65% YoY) and the FY2025 annual result came in at $6.3 million, up 30.47% from the prior year.
- Receivables climbed to $24.1 million in Q4 2025, from $6.3 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $24.1 million in Q4 2025 to a low of $3.3 million in Q4 2022.
- A 5-year average of $6.8 million and a median of $5.0 million in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables sank 35.35% — and 2025, when it soared 439.65%.
- Tracing IMMP's Receivables over 5 years: stood at $5.1 million in 2021, then plunged by 35.35% to $3.3 million in 2022, then gained by 21.06% to $4.0 million in 2023, then gained by 12.48% to $4.5 million in 2024, then soared by 439.65% to $24.1 million in 2025.
- The last three Receivables figures came in at $24.1 million (Q4 2025), $6.3 million (Q2 2025), and $4.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Immutep | 57.14 Mn | -7.95 Mn | - | 24.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.11 Mn |
| Jun 30, 2025 | 6.32 Mn |
| Dec 31, 2024 | 4.47 Mn |
| Jun 30, 2024 | 4.84 Mn |
| Dec 31, 2023 | 3.97 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Dec 31, 2021 | 5.08 Mn |
| Jun 30, 2021 | 4.72 Mn |
| Dec 31, 2020 | 3.88 Mn |
| Jun 30, 2020 | 2.16 Mn |
| Dec 31, 2019 | 3.24 Mn |
| Jun 30, 2019 | 3.64 Mn |
| Dec 31, 2018 | 2.63 Mn |
| Jun 30, 2018 | 2.60 Mn |
| Jun 30, 2017 | 1.65 Mn |
| Mar 31, 2017 | 1.77 Mn |
| Jun 30, 2016 | 125,670.02 |
| Jun 30, 2015 | 245,240.35 |